3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
4
Carcinoma
2
ALK-positive Advanced NSCLC
2
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Carcinoma, Squamous Cell
1
Carcinoma, Large Cell
1
Brain Neoplasms
1
Adenocarcinoma
1
ALK-positive NSCLC
1
ALK+ Advanced NSCLC
1
Interventions
Gemcitabine
14
Cisplatin
13
Capecitabine
11
Oxaliplatin
9
Fluorouracil
9
130-nm albumin-bound paclitaxel
9
Paclitaxel
8
pembrolizumab
7
Ramucirumab
6
Leucovorin
6
Carboplatin
6
Bevacizumab
6
Albumin-Bound Paclitaxel
6
Pemetrexed
4
Nivolumab
4
Irinotecan
4
Everolimus
4
Erlotinib Hydrochloride
4
Docetaxel
4
Cyclophosphamide
4
trastuzumab deruxtecan
3
Radiotherapy
3
Afatinib
3
zolbetuximab
2
pralsetinib
2
cabozantinib
2
Trastuzumab
2
Ipilimumab
2
vosaroxin
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Adenocarcinoma
×
brigatinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA